% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • briand7035 briand7035 Jul 30, 2013 12:23 AM Flag

    Bloomberg, Reuters inadvertantly stoking the runmor mill haphazardly and then no folllowup

    Pfizer in then out then in again. Four competitive bids coming last week. (one that actually materialized would have been awesome.) Amgen lining up financing---We know these reporters could do a followup and the actual participants can't talk if they are in negotiations. but how about some followup or commentary from knowledgeable industry insiders. Is that too much to ask from the headline hacks

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Sometimes sources are reliable and some times they are not.Bloomberg has a good reputation of finding/verifying sources(right 50-70%).Reuters sources have flipflopped on Onyx.
      I believe that Amgen is very serious--could pay close to 145-150$/share.But this process of raising bid price takes tough negotiations.Centerway partners is good at it. Amgen CEO/Chairman has Morgan Stanley experience-so he understands the future price of Amgen with and without Onyx.His future depends on Amgen's stock performance.So expect an announcement in 3-4 weeks.